• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Fonar raises $4.5 million

Article

Four years ago, Fonar was basking in the glow of its $100-million-plus legal victory over GE in a patent issue. Whatever is left from that court battle, however, apparently is not enough. The Tail Wind Fund, which focuses on emerging growth companies,

Four years ago, Fonar was basking in the glow of its $100-million-plus legal victory over GE in a patent issue. Whatever is left from that court battle, however, apparently is not enough. The Tail Wind Fund, which focuses on emerging growth companies, has invested $4.5 million in Fonar, receiving in exchange debentures convertible to Fonar common stock. Fonar issued two series of warrants to the fund. It will file details of the transaction with the SEC. The newfound capital will be used to fund the production of Fonar’s line of MRI devices, including its Indomitable, a stand-up MRI scanner optimized for orthopedic imaging. The company announced earlier this month the sale of an Indomitable to the University of Aberdeen in Scotland.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.